Théa Open Innovation

Théa Open Innovation company information, Employees & Contact Information

Théa Open Innovation is a sister company of Laboratoires Théa. Our aim is to identify, evaluate and support the most innovative developments in eye care, throughout licensing agreements and/or equity investments. In addition of our funding to support the R&D phases to reach proof of concept in human, Théa offers the expertise and capabilities to develop and commercialize innovative therapeutic solutions in Ophthalmology, in order to provide patients and healthcare professionals with tomorrow’s solutions. We work through alliance management. Our partners retain their specific expertise in house and remain leader of their project while they will benefit from Théa’s know how in ophthalmology and funding. So we are happy to talk to all companies, universities, academics, and researchers who have projects in ophthalmology. If you have an innovative eye care project, and you look for partners, feel free to contact us. To know more about Laboratoires Théa expertise in ophthalmology and its international implantation, please visit www.laboratoires-thea.com To know more about us, please visit www.theaopeninnovation.com

Company Details

Employees
12
Founded
-
Address
Clermont Ferrand, Auvergnerhônealpes
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
Lyon.
HQ
Clermont Ferrand, Auvergnerhônealpes
Looking for a particular Théa Open Innovation employee's phone or email?

Théa Open Innovation Questions

News

Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD - Yahoo Finance

Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD Yahoo Finance

Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clini - Yahoo Finance

Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clini Yahoo Finance

Thea Open Innovation returns retinal vascular disease treatment rights to Curacle - koreabiomed.com

Thea Open Innovation returns retinal vascular disease treatment rights to Curacle koreabiomed.com

Top Théa Open Innovation Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant